Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb 24;10(1):84-90.
doi: 10.5114/aoms.2013.36753. Epub 2013 Aug 12.

The AgNORs count in predicting long-term survival in serous ovarian cancer

Leszek Gottwald  1 , Marian Danilewicz  2 , Wojciech Fendler  3 , Jacek Suzin  4 , Michal Spych  1 , Janusz Piekarski  5 , Wieslaw Tylinski  4 , Justyna Chalubinska  1 , Katarzyna Topczewska-Tylinska  6 , Aleksandra Cialkowska-Rysz  7
Affiliations

The AgNORs count in predicting long-term survival in serous ovarian cancer

Leszek Gottwald et al. Arch Med Sci. .

Abstract

Introduction: The value of argyrophilic nucleolar organizer regions (AgNORs) to predict survival in patients with ovarian cancer has not been clearly explained yet. The aim of study was to assess the value of analysis of the mean number of AgNORs per nucleus (mAgNOR) and mean percentage of nuclei with five or more AgNORs per nucleus (pAgNOR) in the prediction of disease-free survival (DFS) and overall survival (OS) in patients with serous ovarian cancer.

Material and methods: The study examined 52 patients treated for serous ovarian cancer with a follow-up period of 2-143 months. After silver staining paraffin specimens from primary surgery, mAgNOR and pAgNOR in cancer cells were counted and analyzed. Age, grading, radicality of surgery and FIGO staging were analyzed as covariates.

Results: Mean mAgNOR equaled 4.4 ±0.9 and pAgNOR equaled 42.2 ±20.8%. Both mAgNOR and pAgNOR were the lowest in G1 tumors. The mAgNOR and pAgNOR were lower in stage I than stage IV cancers. The DFS and OS rates were respectively 15.4% and 21.2%. In univariate analysis FIGO staging, grading, and pAgNOR were associated with worse prognosis, while radicality of surgery remained a significant protective factor in terms of DFS. Higher FIGO staging and older age worsened OS. In multivariate analysis FIGO staging remained significantly associated with both DFS (HR 1.98; 95% CI 1.05-3.71) and OS (HR 1.76; 95% CI 1.00-3.10), while age affected OS rates (HR 1.78; 95% CI 1.04-2.95).

Conclusions: mAgNOR and pAgNOR are useful markers of cellular kinetics. Prospective studies in larger populations are needed to confirm these results in terms of AgNORs' effects on survival.

Keywords: argyrophilic; nucleolar organizer regions; prognostic factors; serous ovarian cancer; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
AgNORs in G2 serous ovarian cancer, 1000× magnification. After silver staining, NORs can be easily identified as black dots exclusively situated throughout the nucleolar area, and are called AgNORs (arrows)
Figure 2
Figure 2
pAgNOR analysis and DFS
Figure 3
Figure 3
mAgNOR analysis and DFS
Figure 4
Figure 4
pAgNOR analysis and OS
Figure 5
Figure 5
mAgNOR analysis and OS
See this image and copyright information in PMC

References

    1. Linasmita V, Pattaraarchachai J, Daengdeelert P. Prognostic factors for survival of epithelial ovarian cancer. Int J Gynaecol Obstet. 2004;85:66–9. - PubMed
    1. Benedet JL, Bender H, 3rd, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines for gynaecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obsetet. 2000;70:209–62. - PubMed
    1. Ozgun MT, Turkyilmaz C. A giant ovarian mucinous cystadenoma in an adolescent: a case reprt. Arch Med Sci. 2009;5:281–3.
    1. Gora E, Zelazowski MJ, Gottwald L, Bienkiewicz A, Bednarek AK. Detection of circulating carcinoma in peripheral blood collected from patients with ovarian cancer by using different molecular markers – a preliminary report. Arch Med Sci. 2006;2:101–7.
    1. Milovic-Kovacevic M, Starnatovic L, Popov I, Radosevic-Jelic L, Kezic I. Platinum sensitive relapsed epithelial ovarian cancer: not all the patients benefit from reinduction with carboplatin and paclitaxel. Med Sci Monit. 2010;16:CR549–54. - PubMed

LinkOut - more resources